Cannabis Testing Services Market

The global cannabis testing services market is expected to be valued at US$ 2.80 Billion in 2026 and is projected to reach US$ 7.14 Billion by 2033, growing at a CAGR of 14.3% between 2026 and 2033.

The U.S. Cannabis Regulatory Authority landscape spanning over 38 state-level adult-use or medical programmes mandates certificate-of-analysis (COA) documentation at multiple supply-chain stages, sustaining consistent laboratory demand. Eurofins Scientific, the world's largest network of food and pharmaceutical testing laboratories, has strategically expanded its cannabis testing division since 2022, signalling institutional confidence in the sector's long-term compliance-driven revenue floor.

• North America leads the global decorated apparel market with 35.8% share in 2026, driven by strong corporate branding, promotional product demand, and a well-established apparel decoration industry.
• The global decorated apparel market is projected to grow at a 13.1% CAGR between 2026 and 2033, fueled by rising e-commerce, on-demand printing, and increasing demand for customized apparel.
• Screen printing holds the largest product segment with 42.6% market share due to its cost-effectiveness, high production efficiency, and suitability for large-volume orders.
• Digital printing is expected to be the fastest-growing decoration technology, supported by advancements in direct-to-garment printing and increasing demand for short-run, personalized apparel.
• Sustainable apparel decoration presents the biggest growth opportunity, driven by rising adoption of eco-friendly inks, waterless printing technologies, and stricter environmental compliance standards.

• Mandatory State-Level Compliance Testing Regimes

Compliance testing mandates are the single most durable demand driver in the cannabis testing services sector. Across the United States, states including California, Colorado, and Illinois require licensed operators to submit cannabis products for potency testing, heavy metal screening, pesticide residue analysis, and residual solvent screening before retail distribution. The California Department of Cannabis Control (DCC) updated its testing regulations in 2023, expanding the list of required pesticide analytes and tightening acceptable limits directly increasing the volume and complexity of tests per batch. Cultivators and processors cannot legally sell product without a laboratory-issued COA, making third-party testing non-discretionary expenditure regardless of economic conditions.

• Laboratory Accreditation Backlogs and Workforce Constraints

Accreditation under ISO/IEC 17025:2017 the international standard governing testing and calibration laboratory competence is mandatory for legal-market laboratory operation in most regulated jurisdictions. The accreditation process through bodies such as the American Association for Laboratory Accreditation (A2LA) and ANSI National Accreditation Board (ANAB) typically requires 12–24 months, creating a structural bottleneck. Combined with a persistent shortage of analytical chemists trained in cannabis-specific matrices, laboratory capacity has failed to scale proportionally with market legalisation, compressing throughput and constraining competitive entry.

• Point-of-Collection and Rapid Testing Technology Integration

The proliferation of portable chromatography and lateral flow immunoassay technologies is opening a new on-site testing services segment for large-scale cultivators and processors. Companies including Purpl Systems have commercialised near-infrared (NIR) spectrometry devices enabling real-time cannabinoid potency estimation at the grow facility, complementing rather than replacing third-party laboratory confirmation testing. This creates a two-tier service model: rapid on-site triage testing purchased by cultivators for harvest optimisation, followed by regulatory-grade laboratory analysis. Laboratories that integrate device calibration, data validation, and regulatory reporting services into a single contract will capture both revenue streams.

• Service Analysis

Potency Testing accounts for 29.8% of the global cannabis testing services market in 2026, equivalent to US$ 0.83 Billion. Its dominance reflects universal regulatory mandates: every licensed cannabis product sold in legal markets from flower to edibles and concentrates requires a validated THC and CBD potency declaration.

Dispensaries and consumers rely on these figures for dosing accuracy, while regulators use them to enforce label-claim compliance. High-performance liquid chromatography (HPLC) remains the gold-standard analytical method for potency quantification, and laboratories with validated HPLC workflows command premium per-test pricing from both cultivators and finished-product manufacturers.

Pesticide screening is the fastest-growing service segment, accelerated by several state-level regulatory expansions between 2022 and 2024. The Oregon Liquor and Cannabis Commission (OLCC) expanded its required pesticide panel to over 59 analytes in recent regulatory cycles, reflecting growing toxicological concern about systemic pesticides in inhalable cannabis products. Laboratories investing in liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrumentation capable of detecting parts-per-billion residue levels are capturing premium-priced contract testing from cultivators managing complex integrated pest management programmes.

• End Use Analysis

Cannabis Cultivators/Growers account for 57.4% of the global cannabis testing services market in 2026, equivalent to US$ 1.61 Billion. Growers represent the primary point of regulatory obligation: mandatory pre-harvest and pre-sale testing applies universally to licensed cultivation operations.

Large multi-state operators (MSOs) such as Curaleaf Holdings and Trulieve Cannabis Corp. maintain ongoing annual testing contracts with accredited laboratories, generating predictable, high-volume revenue streams. Beyond compliance, cultivators use terpene profiling and potency data to differentiate premium cultivars in a crowded retail environment making testing a marketing asset, not merely a regulatory cost.

Cannabis drug manufacturers represent the fastest-growing end-use segment, driven by expanding pharmaceutical cannabis pipelines. GW Pharmaceuticals (now part of Jazz Pharmaceuticals) established the clinical-grade testing standard for cannabis APIs, and a growing cohort of biotechnology firms pursuing FDA Investigational New Drug (IND) applications for cannabinoid therapeutics now require Good Manufacturing Practice (GMP)-compliant analytical testing. This segment demands validated methods, batch record documentation, and stability testing protocols that command significantly higher per-project revenue than standard compliance screening.

• North America Cannabis Testing Services Market Trends and Insights

North America accounts for 61.8% of the global cannabis testing services market in 2026, representing US$ 1.73 Billion. The region's dominance rests on the world's most mature licensed cannabis infrastructure, with the National Conference of State Legislatures (NCSL) tracking active adult-use programmes across more than 24 U.S. states. Federal reclassification discussions under the Drug Enforcement Administration (DEA) rulemaking process initiated in 2024 are expected to intensify pharmaceutical-grade testing demand through the forecast period.

U.S. Cannabis Testing Services Market Size

The U.S. cannabis testing services market represents 82.6% of the North America regional market in 2026, equivalent to US$ 1.43 Billion. Demand is anchored by mandatory COA requirements across multi-state licensed markets, with testing frequency per batch increasing as states expand required analyte panels. The ongoing DEA rescheduling process moving cannabis from Schedule I to Schedule III under the Controlled Substances Act is expected to unlock interstate laboratory commerce and catalyse laboratory consolidation.

Canada Cannabis Testing Services Market Size

The Canada cannabis testing services market represents 16.2% of the North America regional market in 2026, equivalent to US$ 0.28 Billion. Health Canada mandates testing under the Cannabis Act (Bill C-45) for potency, microbial contaminants, heavy metals, and residual solvents across all licensed producer categories. Increasing licensed producer consolidation with larger operators internalising some analytical functions may moderate third-party testing growth, though export-market compliance testing represents a developing incremental revenue opportunity.

• Asia Pacific Cannabis Testing Services Market Trends and Insights

Asia Pacific accounts for 10.6% of the global cannabis testing services market in 2026, representing US$ 0.30 Billion, and is the fastest-growing regional market at an estimated CAGR of 17.8% through 2033. Australia's Therapeutic Goods Administration framework for medicinal cannabis and emerging regulatory activity across Thailand and South Korea are the primary acceleration forces. The 17.8% CAGR reflects a market transitioning from negligible base to structured regulatory infrastructure across multiple jurisdictions simultaneously.

Australia Cannabis Testing Services Market Size

The Australia cannabis testing services market represents 29.5% of the Asia Pacific regional market in 2026, equivalent to US$ 0.09 Billion. The Therapeutic Goods Administration (TGA) mandates rigorous analytical testing for all medicinal cannabis products under the Narcotic Drugs Act 1967, including potency, pesticide residue, and heavy metal quantification. Expanding patient access schemes and rising licensed cultivator numbers position Australia as the region's most structurally developed cannabis testing services market through the medium term.

Japan Cannabis Testing Services Market Size

The Japan cannabis testing services market represents 20.8% of the Asia Pacific regional market in 2026, equivalent to US$ 0.06 Billion. Japan's 2023 Cannabis Control Act revision permitting the use of cannabis-derived medicines marks a foundational regulatory shift enabling legitimate testing activity for the first time in the modern era. As pharmaceutical-grade hemp-derived cannabinoid products enter the approval pipeline under the Pharmaceuticals and Medical Devices Agency (PMDA), demand for validated analytical testing is expected to expand incrementally through 2030.

South Korea Cannabis Testing Services Market Size

The South Korea cannabis testing services market represents 14.3% of the Asia Pacific regional market in 2026, equivalent to US$ 0.04 Billion. South Korea's Ministry of Food and Drug Safety (MFDS) approved the importation and use of Epidiolex in 2019, creating an initial regulatory precedent for pharmaceutical cannabis. A small but growing pipeline of cannabinoid drug development activity within South Korean biotechnology firms is beginning to generate demand for GMP-compliant analytical testing services, with the market expected to scale as domestic R&D investment increases.

The cannabis testing services industry is moderately fragmented, with no single player holding dominant global share. Competition turns primarily on accreditation breadth, analytical method validation, and turnaround time not price alone. Eurofins Scientific operates the most geographically diversified cannabis testing network, leveraging its pharmaceutical and food safety infrastructure for cross-market scalability.

SC Labs and Green Leaf Lab maintain strong positions in the U.S. licensed-market segment through established cultivator relationships and rapid COA delivery. SGS Société Générale de Surveillance SA competes in pharmaceutical-adjacent cannabis testing across Europe and Canada, where its existing ISO 17025 accreditations provide immediate credibility. Specialised boutique laboratories including PhytoVista Laboratories in the United Kingdom compete on method expertise in novel cannabinoid and terpene characterisation, serving premium research and pharmaceutical clients.

• Saskatchewan Research Council (SRC)
• SC Labs
• SGS Société Générale de Surveillance SA (SGS Canada Inc.)
• Dr. Robert Shrewsbury & the UNC Eshelman School of Pharmacy (PharmLabs)
• Green Leaf Lab
• Eurofins Scientific
• PhytoVista Laboratories (British Cannabis Group)
• British Cannabis
• ADACT Medical Ltd.
• Laboratorium Dr. Liebich
• AZ Biopharm GmbH

By Service

• Potency Testing
• Terpene Profiling
• Heavy Metal Testing
• Pesticide Screening
• Microscopy Testing
• Residual Solvent Screening
• Others

By End Use

• Cannabis Cultivators/Growers
• Cannabis Drug Manufacturers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa